GSK plc Form 6-K Summary
Business Context and Reporting Period
GSK plc filed a Form 6-K for September 2026, signed September 22, 2026. The filing reports transactions in GSK securities by directors and other persons discharging managerial responsibilities or persons closely associated with them. It is not an earnings or operational update.
GSK is a global biopharmaceutical company focused on vaccines, specialty medicines and general medicines.
Reported Transactions
| Person | Position | Security | Transaction | Price | Volume | Date and Venue |
|---|---|---|---|---|---|---|
| Sir Jonathan Symonds | Non-Executive Chair | Ordinary shares | Purchase | £18.8110 | 1,500 | September 18, 2026; London Stock Exchange |
| Elizabeth McKee Anderson | Independent Non-Executive Director | ADSs | Purchase | $49.8534 | 626 | September 18, 2026; New York Stock Exchange |
| Charles Bancroft | Senior Independent Non-Executive Director | ADSs | Purchase | $49.8534 | 1,734 | September 18, 2026; New York Stock Exchange |
| Dr Anne Beal | Independent Non-Executive Director | ADSs | Purchase | $49.8534 | 637 | September 18, 2026; New York Stock Exchange |
| Dr Hal Dietz | Independent Non-Executive Director | ADSs | Purchase | $49.8534 | 768 | September 18, 2026; New York Stock Exchange |
| Dr Jeannie Lee | Independent Non-Executive Director | ADSs | Purchase | $49.8534 | 653 | September 18, 2026; New York Stock Exchange |
| Dr Vishal Sikka | Independent Non-Executive Director | ADSs | Purchase | $49.8534 | 994 | September 18, 2026; New York Stock Exchange |
| Roy Jackobs | Independent Non-Executive Director | Ordinary shares | Purchase | £18.8100 | 936 | September 18, 2026; London Stock Exchange |
Financial Metrics and Material Changes
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating and financial metrics. It does not present financial results or a clear comparison with a prior period.
The material disclosure is the reported purchase of GSK ordinary shares and ADSs by the identified directors on September 18, 2026. The filing does not describe any related change in business performance, strategy, capital structure or outlook.
Outlook, Risks and Unusual Items
No management outlook, forecasts, risk factors, contingencies or unusual operating items are disclosed. The transactions are individual insider purchases, each reported as a single transaction.
Important Facts to Verify
- Confirm the security conversion relationship between GSK ordinary shares and ADSs when comparing the reported volumes.
- Verify the transaction prices, volumes, dates and trading venues against applicable market records.
- Determine whether these purchases reflect board compensation arrangements, investment decisions or other contractual circumstances not explained in the filing.
- Use GSK’s latest earnings release or Form 20-F to assess revenue, profitability, cash flow, leverage, liquidity and current guidance, because those metrics are absent from this Form 6-K.